Showing 1 - 2 results of 2 for search 'L. De la Cruz-Merino', query time: 0.03s Refine Results
  1. 1
    Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

    Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant by P. Neven, P. A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G. V. Bianchi, M. Martín, A. Nusch, G. S. Sonke, L. De la Cruz-Merino, J. T. Beck, J. P. Zarate, Y. Wang, A. Chakravartty, C. Wang, D. J. Slamon

    Published 2023-08-01
    Get full text
    Article
  2. 2
    Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

    Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study by L. de la Cruz-Merino, M. Gion, J. Cruz, JL. Alonso-Romero, V. Quiroga, F. Moreno, R. Andrés, M. Santisteban, M. Ramos, E. Holgado, J. Cortés, E. López-Miranda, A. Cortés, F. Henao, N. Palazón-Carrión, L. M. Rodriguez, I. Ceballos, A. Soto, A. Puertes, M. Casas, S. Benito, M. Chiesa, S. Bezares, R. Caballero, C. Jiménez-Cortegana, V. Sánchez-Margalet, F. Rojo

    Published 2022-12-01
    Get full text
    Article

Search Tools: